HTX-011 in Spinal Surgery
A Phase 2, Two-Part, Multicenter Study of HTX-011 in Spinal Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Sophie Visonneau, PhD
- Phone Number: 858-251-7232
- Email: svisonneau@herontx.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Arizona Research Center
-
-
California
-
Pasadena, California, United States, 91105
- Lotus Clinical Research, LLC
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Kansas Spine and Specialty Hospital
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Spine Institute of Louisiana
-
-
New Jersey
-
Summit, New Jersey, United States, 07901
- Overlook Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27704
- M3 Emerging Medical Research, LLC
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center - University Hospital
-
-
Texas
-
Austin, Texas, United States, 78746
- Austin Neurosurgeons
-
Bellaire, Texas, United States, 77401
- First Surgical Hospital
-
Houston, Texas, United States, 77008
- Houston Heights Hospital
-
San Antonio, Texas, United States, 78258
- South Texas Spine & Surgical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia.
- Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study.
Exclusion Criteria:
- Has a contraindication of a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has a history of severe allergic reaction due to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
- Has functioning intrathecal drug pump or spinal cord stimulator.
- Opioid use for most days within the last 3 months.
- Has initiated treatment with selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
- Has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation.
- Has impaired balance and is at risk of falling.
- Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.
- Has undergone 3 or more surgeries within 12 months.
- Has a known history of glucose-6-phosphate dehydrogenase deficiency.
- Has History of liver cirrhosis, having an aspartate aminotransferase >3 × the upper limit of normal (ULN), or having an alanine aminotransferase >3 × ULN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1: Bupivacaine HCl
Bupivacaine HCl without epinephrine, via injection into the surgical site.
|
100 mg administered via injection into the surgical site.
|
|
Experimental: Cohort 2: HTX-011
HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
|
Applicator for instillation.
HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
|
|
Experimental: Cohort 3: HTX-011
HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
|
Applicator for instillation.
HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Serious Adverse Events
Time Frame: From the time the subject signs the ICF through the Day 29 Visit
|
From the time the subject signs the ICF through the Day 29 Visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Baseline through 120 hours
|
Baseline through 120 hours
|
|
Time of occurrence of maximum concentration (Tmax)
Time Frame: Baseline through 120 hours
|
Baseline through 120 hours
|
|
Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)
Time Frame: Baseline through 120 hours
|
Baseline through 120 hours
|
|
Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)
Time Frame: Baseline through 120 hours
|
Baseline through 120 hours
|
|
Apparent terminal half-life (t½)
Time Frame: Baseline through 120 hours
|
Baseline through 120 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anesthetics, Local
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Bupivacaine
- Epinephrine
Other Study ID Numbers
Other Study ID Numbers
- HTX-011-221
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.